太龙药业（600222）发布2025年度业绩暨现金分红说明会公告
会议详情及投资者参与方式全解读
河南太龙药业股份有限公司（以下简称“公司”）于2026年4月16日发布了关于召开2025年年度业绩暨现金分红说明会的公告。会议旨在让投资者更全面深入地了解公司2025年度的经营成果、财务状况以及利润分配相关事宜，同时为投资者与公司高管搭建直接沟通的平台，听取投资者意见和建议。
公告要点及对投资者的影响
- 说明会时间：2026年4月24日（星期五）13:00-14:45
- 说明会地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/）
- 说明会形式：视频结合网络文字互动
- 投资者提问渠道：
- 2026年4月17日至4月23日16:00期间，投资者可登录上证路演中心网站首页点击“提问预征集”栏目提前提交问题。
- 或将问题发送至公司邮箱：[email protected]。
- 会议参与人员：公司董事长、独立董事、财务负责人、董事会秘书（如有特殊情况，人员可能调整）。
- 会后回看：投资者可通过上证路演中心网站回看说明会主要内容。
对股东及股价的潜在影响
本次说明会将详细解读公司最新发布的《2025年年度报告》和《2025年度利润分配方案》，这些内容对公司经营状况、分红政策等关键信息进行披露。利润分配方案及分红政策历来是市场高度关注的焦点，直接影响到投资者的回报预期和市场对公司价值的判断。公司表示，将在说明会上对投资者普遍关心的问题进行回应，包括但不限于财务表现、未来发展规划及分红安排等，这些内容均可能对公司股价产生影响。
投资者若对公司经营、财务、分红等事项有疑问，建议提前通过官网或邮箱提交问题，积极参与互动，为自身投资决策提供更多信息。
联系方式
结语
本次业绩说明会不仅是公司与投资者之间沟通的重要桥梁，也是投资者判断公司未来发展和回报预期的重要窗口。尤其对于关注分红政策与公司未来发展方向的股东而言，建议密切关注此次说明会的内容及后续披露。
免责声明：本文仅为信息整理与汇总，不构成任何投资建议。投资者应结合自身判断及风险承受能力理性投资，具体信息以公司公告及官方文件为准。
Taloph Pharmaceutical (600222) to Hold 2025 Annual Results and Cash Dividend Briefing: Key Details for Investors
Comprehensive Overview and Investor Participation Guide
Henan Taloph Pharmaceutical Co., Ltd. (“the Company”) announced on April 16, 2026, that it will hold a briefing session on its 2025 annual results and cash dividend plan. The purpose of the event is to provide investors with in-depth and comprehensive information on the Company’s 2025 performance, financial status, and dividend distribution, as well as to offer investors a direct channel for communication with senior management and to solicit their feedback and suggestions.
Key Points and Potential Impact on Investors
- Briefing Time: April 24, 2026 (Friday), 13:00-14:45 (Beijing time)
- Location: Shanghai Stock Exchange Roadshow Center (URL: https://roadshow.sseinfo.com/)
- Format: Video and online text interaction
- Investor Q&A Channels:
- From April 17 to April 23, 2026, 16:00, investors can pre-submit questions via the “Question Collection” section on the SSE Roadshow Center homepage.
- Alternatively, questions can be emailed to: [email protected].
- Participants: Company Chairman, Independent Directors, Chief Financial Officer, Board Secretary (subject to adjustments if necessary).
- Replay: Investors can review the briefing’s main content on the SSE Roadshow Center website after the event.
Potential Impact on Shareholders and Share Price
The briefing will provide a detailed explanation of the recently released “2025 Annual Report” and “2025 Profit Distribution Plan,” disclosing critical information such as the Company’s operating performance and dividend policy. Dividend policies and profit distribution plans are closely watched by the market, as they directly affect investor returns and influence market valuation of the Company. The Company will address widely concerned investor questions during the session, including but not limited to financial performance, future strategies, and dividend arrangements, all of which could have a material impact on the share price.
Investors with questions related to operations, financials, or dividend matters are encouraged to submit their queries in advance through the official website or email, and to actively participate in the event to inform their investment decisions.
Contact Information
Conclusion
This annual results briefing is a vital communication channel between the Company and its investors, offering essential insights for evaluating the Company’s future prospects and expected returns. Shareholders, especially those focused on dividends and future growth, are advised to pay close attention to the session and subsequent disclosures.
Disclaimer: The above is for informational purposes only and does not constitute investment advice. Investors should make decisions based on their own judgment and risk tolerance. For specifics, refer to official Company announcements and documents.
View 太龙药业 Historical chart here
